RT Journal Article SR Electronic T1 The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis JF European Respiratory Review JO EUROPEAN RESPIRATORY REVIEW FD European Respiratory Society SP 200269 DO 10.1183/16000617.0269-2020 VO 29 IS 157 A1 Manuela Platé A1 Delphine Guillotin A1 Rachel C Chambers YR 2020 UL http://err.ersjournals.com/content/29/157/200269.abstract AB Idiopathic pulmonary fibrosis (IPF) is characterised by the progressive deposition of excessive extracellular matrix proteins within the lung parenchyma and represents the most rapidly progressive and fatal of all fibrotic conditions. Current anti-fibrotic drugs approved for the treatment of IPF fail to halt disease progression and have significant side-effect profiles. Therefore, there remains a pressing need to develop novel therapeutic strategies for IPF. Mammalian target of rapamycin (mTOR) forms the catalytic subunit of two complexes, mTORC1 and mTORC2. mTORC1 acts as critical cellular sensor which integrates intracellular and extracellular signals to reciprocally regulate a variety of anabolic and catabolic processes. The emerging evidence for a critical role for mTORC1 in influencing extracellular matrix production, metabolism, autophagy and senescence in the setting of IPF highlights this axis as a novel therapeutic target with the potential to impact multiple IPF pathomechanisms.Current evidence supports the scientific rationale for targeting the mTOR pathway in idiopathic pulmonary fibrosis https://bit.ly/33OQiYf